Executive Summary
Both filings in this stream highlight acute regulatory distress for small-cap companies facing delisting from major US exchanges. Grove Collaborative Holdings, Inc. received an NYSE non-compliance notice for failing to meet minimum market capitalization and stockholders' equity thresholds, a clear negative signal with high materiality (9/10). Hoth Therapeutics, Inc.
(now Rocket One Inc.) faces a Nasdaq delisting notice while simultaneously announcing a strategic pivot to AI and space computing, creating a mixed sentiment (6/10) scenario. Neither filing provides period-over-period financial comparisons, insider trading data, or forward-looking guidance, limiting trend analysis. The overarching theme is the precarious financial health of micro-cap issuers, where regulatory non-compliance triggers existential risks. No portfolio-level patterns or sector themes emerge beyond the individual company distress signals.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from August 10, 2026.
Investment Signals (6)
- Grove Collaborative Holdings ↓ (BEARISH)▲
Received NYSE non-compliance notice for failing $50M market cap and $50M equity thresholds over 30 consecutive days; must submit a business plan within 45 days or face delisting
- Hoth Therapeutics (Rocket One) (BEARISH)▲
Faces Nasdaq delisting notice (Item 3.01) while pivoting to AI/space computing; no commercial product and requires substantial additional capital
- Grove Collaborative ↓ (BEARISH)▲
Intends to submit a compliance plan to NYSE, but failure to regain compliance within nine months leads to delisting; no insider buying or capital allocation moves reported to signal confidence
- Hoth Therapeutics (Rocket One) (MIXED)▲
Accepted into Seagate Partner Program, gaining access to enterprise storage resources; pivot to AI infrastructure and nanomagnetic chip technology is speculative with no revenue
- Grove Collaborative ↓ (BEARISH)▲
No forward-looking guidance, insider transactions, or period-over-period financial data provided in the filing, indicating limited transparency
- Hoth Therapeutics (Rocket One) (BEARISH)▲
No insider trading activity, capital allocation changes, or financial ratios disclosed; the pivot lacks concrete milestones or funding commitments
Risk Flags (6)
- Grove Collaborative/Delisting Risk↓ [HIGH RISK]▼
NYSE non-compliance for market cap and equity; 45-day deadline to submit business plan; failure leads to delisting within nine months; stock ticker GROV under immediate pressure
- Hoth Therapeutics (Rocket One)/Delisting Risk [HIGH RISK]▼
Nasdaq delisting notice (Item 3.01) active; name change to Rocket One does not resolve regulatory non-compliance; ticker RKTO at risk of suspension
- Hoth Therapeutics (Rocket One)/Business Model Risk [HIGH RISK]▼
Licensed technologies remain early-stage with no commercial product; pivot from biotech to AI/space requires substantial additional capital with no funding plan disclosed
- Grove Collaborative/Liquidity Risk↓ [MODERATE RISK]▼
No financial data provided; failure to meet $50M equity threshold suggests potential liquidity or solvency issues; no insider buying to offset concern
- Hoth Therapeutics (Rocket One)/Execution Risk [MODERATE RISK]▼
Seagate Partner Program acceptance is non-financial; pivot to orbital economy and nanomagnetic chips is unproven; no timeline for product development
- Both Companies/Regulatory Risk [HIGH RISK]▼
Trading suspensions or delistings could occur if compliance plans are rejected; investors face potential total loss of liquidity
Opportunities (5)
- Hoth Therapeutics (Rocket One)/Pivot Catalyst (SPECULATIVE OPPORTUNITY)◆
Strategic pivot to AI infrastructure and space computing could attract speculative capital if the company secures funding or partnerships; Seagate partnership provides credibility
- Grove Collaborative/Compliance Plan↓ (TURNAROUND OPPORTUNITY)◆
If Grove submits a credible business plan within 45 days and shows a path to regain compliance, the stock could rally on reduced delisting risk; monitor for plan details
- Hoth Therapeutics (Rocket One)/Name Change (SPECULATIVE OPPORTUNITY)◆
Rebranding to Rocket One may generate retail interest in AI/space themes; low float micro-cap could see volatility-driven trading opportunities
- Grove Collaborative/Valuation Gap↓ (SPECULATIVE OPPORTUNITY)◆
If Grove regains compliance, current depressed valuation may offer entry point; no financial data available to assess intrinsic value
- Hoth Therapeutics (Rocket One)/Short Squeeze Potential (SPECULATIVE OPPORTUNITY)◆
High delisting risk and speculative pivot could attract short sellers; any positive news (funding, partnership) could trigger a squeeze
Sector Themes (4)
- Micro-Cap Delisting Wave◆
Both filings involve small-cap companies (<$50M market cap) facing exchange non-compliance, reflecting a broader trend of tightening listing standards and financial fragility among micro-caps
- Pivot to AI/Space as Survival Tactic◆
Hoth Therapeutics' pivot from biotech to AI/space computing exemplifies a pattern where distressed companies rebrand to speculative sectors to attract capital, often without viable products
- Lack of Financial Transparency◆
Neither filing includes period-over-period comparisons, insider activity, or forward-looking guidance, highlighting a common issue where distressed micro-caps provide minimal disclosure
- Regulatory Risk Concentration◆
Both companies face imminent delisting, underscoring the binary risk for investors in small-cap equities where exchange compliance is a primary catalyst
Watch List (6)
-
45-day deadline to submit NYSE compliance plan (due ~September 21, 2026); monitor for plan details and market reaction
- Hoth Therapeutics (Rocket One)👁
Nasdaq delisting proceedings; watch for any funding announcements, partnership updates, or appeal filings
- Both Companies👁
SEC trading suspension filings; any 8-K updates on compliance status or exchange decisions
-
Stock price and market cap trends over next 30 trading days; need to track if $50M thresholds are approached
- Hoth Therapeutics (Rocket One)👁
Progress on Seagate partnership and any revenue generation from AI/space pivot; watch for capital raises
- Both Companies👁
Insider trading activity post-filing; any insider buying would signal management confidence, selling would confirm distress
Filing Analyses
(2)
11-08-2026
Grove Collaborative Holdings, Inc. received a notice from the NYSE on August 7, 2026, for non-compliance with continued listing standards requiring a minimum average market capitalization of $50.0 million and stockholders' equity of $50.0 million over 30 consecutive trading days. The company must submit a business plan within 45 days to demonstrate how it expects to regain compliance within nine months. The notice does not immediately affect the listing of the company's securities, but the failure to regain compliance could lead to delisting.
- · The company's Class A common stock (ticker: GROV) is listed on the NYSE.
- · The company is an emerging growth company as defined under SEC rules.
- · The company intends to submit a plan to regain compliance as required by NYSE rules.
- · A press release regarding the NYSE notice was issued on August 11, 2026, and is attached as Exhibit 99.1.
11-08-2026
Rocket One Inc. (formerly Hoth Therapeutics, Inc.) announced its acceptance into the Seagate Partner Program, gaining access to enterprise storage resources as it advances its AI, space, and defense computing strategy. The company is pivoting from biotechnology to focus on next-generation AI infrastructure, nanomagnetic chip technology, and orbital economy applications. However, the filing also reveals the company faces a delisting notice (Item 3.01) and its licensed technologies remain early-stage with no commercial product, requiring substantial additional capital.
- · The filing is an 8-K with Items 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule) and 8.01 (Other Events).
- · The company changed its name from Hoth Therapeutics, Inc. to Rocket One Inc. on July 12, 2017.
- · Rocket One's common stock trades on Nasdaq under the symbol RKTO.
- · The company's biotechnology pipeline (HT-001, HT-KIT, HT-ALZ, GDNF-based metabolic program) will continue under a wholly owned subsidiary.
- · The licensed nanomagnetic technologies have not been fabricated as integrated devices, validated in space environments, or qualified for any commercial or government program.
- · The company faces risks including the need for substantial additional capital, long development timelines, competition from larger firms, and potential loss of license rights if diligence milestones under the Virginia Commonwealth University license agreements are not met.
Get daily alerts with 6 investment signals, 6 risk alerts, 5 opportunities and full AI analysis of all 2 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US SEC Trading Suspension Halt Orders
🇺🇸 More from United States
View all →August 12, 2026
US Pre-Market SEC Filings Roundup — August 12, 2026
US Pre-Market SEC Filings Roundup
August 12, 2026
USA Corporate Events Calendar — August 12, 2026
USA Corporate Events Calendar
August 12, 2026
USA Earnings Calls Schedule — August 12, 2026
USA Earnings Calls Schedule
August 12, 2026
US Corporate Board Director Changes SEC Filings — August 12, 2026
US Corporate Board Director Changes SEC Filings